CytomX Therapeutics (STU:6C1) Change In Payables And Accrued Expense : €-8.6 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Change In Payables And Accrued Expense?

CytomX Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €-2.7 Mil. It means CytomX Therapeutics's Accounts Payable & Accrued Expense declined by €2.7 Mil from Dec. 2024 to Mar. 2025 .

CytomX Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €-9.5 Mil. It means CytomX Therapeutics's Accounts Payable & Accrued Expense declined by €9.5 Mil from Dec. 2023 to Dec. 2024 .

CytomX Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for CytomX Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Change In Payables And Accrued Expense Chart

CytomX Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-9.78

6.57

-9.17

-7.76

-9.48

CytomX Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-3.55	-2.88	2.56	-5.55	-2.69

CytomX Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.6 Mil.

CytomX Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines